Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 1853-1861

  Parkins, M D ^a,b,c   Elborn, J S ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Achromobacter xylosoxidans; Burkholderia cepacia; Ceftobiprole; Doripenem; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tigecycline

Indexed keywords

ANTIINFECTIVE AGENT; BAL 30376; CARBAPENEM DERIVATIVE; CB 182804; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; DORIPENEM; GLYCYLCYCLINE DERIVATIVE; ME 1071; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG;

ACHROMOBACTER XYLOSOXIDANS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA; VOMITING;

EID: 77955627319     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq245     Document Type: Review

References (84)

1. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3-management. Thorax 2008; 63: 180-4.
2. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007; 62: 360-7.
3. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006; 148: 259-64.
4. Spicuzza L, Sciuto C, Vitaliti G et al. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis 2009; 28: 191-5.
5. Britto MT, Kotagal UR, Hornung RW et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121: 64-72.
6. Mayer-Hamblett N, Rosenfeld M, Emerson J et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-5.
7. Robson M, Abbott J, Webb K et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992; 47: 684-9.
8. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-8.
9. Vinks AA, Brimicombe RW, Heijerman HG et al. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40: 125-33.
10. Hubert D, Le Roux E, Lavrut T et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-6.
11. Razvi S, Quittell L, Sewall A et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136: 1554-60.
12. Lambiase A, Raia V, Del Pezzo M et al. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006; 6:4.
13. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-30.
14. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009; 8: 386-91.
15. Valenza G, Tappe D, Turnwald D et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7: 123-7.
16. Lechtzin N, John M, Irizarry R et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73: 27-33.
17. Merlo CA, Boyle MP, Diener-West M et al. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007; 132: 562-8.
18. Ren CL, Morgan WJ, Konstan MW et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007; 42: 513-8.
19. Dasenbrook EC, Merlo CA, Diener-West M et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 814-21.
20. Sawicki GS, Rasouliyan L, Pasta DJ et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008; 43: 1117-23.
21. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
22. Sacchidanand S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
23. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
24. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
25. EUCAST. European Committee on Antimicrobial Susceptibility Testing: Breakpoint Tables for Interpretation of MICs and Zone Diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.1.pdf (6 May 2010, date last accessed).
26. Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-4.
27. Fritsche T, Strabala P, Sader HS et al. Activity of tigecycline tested against non-fermentative Gram-negative (NFB) bacilli other than P. aeruginosa. In: Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, 2004. Abstract 1205. Infectious Diseases Society of America, Arlington, VA, USA.
28. Livermore DM, Hope R, Brick G et al. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii55-63.
29. Caillon JLV, Carrere J, Pelletier M et al. In vitro activity of meropenem (MEM), colistin (CS) and tigecycline (TGC) against Achromobacter xylosoxidans (AX) isolated from cystic fibrosis patients. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract E-1469. American Society for Microbiology, Washington, DC, USA.
30. Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009; 34: 121-30.
31. Florescu I, Beuran M, Dimov R et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 Suppl 1: i17-28.
32. Wallace RJ Jr, Brown-Elliott BA, Crist CJ et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-7.
33. Wallace R, Dukart G, Brown-Elliott BA et al. Experience with tigecycline in infections due to Mycobacterium abscessus complex and Mycobacterium chelonae. In: Abstracts of the Nineteenth European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, 2009. Abstract 1416. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
34. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009; 34:e1-9.
35. Meagher AK, Ambrose PG, Grasela TH et al. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165-71.
36. Conte JE Jr, Golden JA, Kelly MG et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-9.
37. Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-52.
38. Naber N, Redman R, Kotey P et al. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis. In: Abstracts of the Seventeenth Congress of Clinical Microbiology and Infectious Diseases and the Twenty-fifth International Congress of Chemotherapy, 2007, Munich, Germany. Abstract 833.
39. Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-83.
40. Rea-Neto A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-26.
41. Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36: 1089-96.
42. Sahm D. In vitro activity of doripenem. Clin Infect Dis 2009; 49 Suppl 1: S11-6.
43. Chen Y, Garber E, Zhao Q et al. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2510-1.
44. Chastre J, Jiang J, Kaniga K et al. Efficacy of doripenem against Pseduomonas aerguionsa in nosocomial pneumonia, including ventillator-associated pneuomnia. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infections Diseases, Barcelona, 2008. Abstract 556. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
45. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-92.
46. Sakyo S, Tomita H, Tanimoto K et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006; 59: 220-8.
47. Chihara S, Smith G, Petti CA. Carbapenem susceptibility patterns for clinical isolates of Mycobacterium abscessus determined by the Etest method. J Clin Microbiol 2010; 48: 579-80.
48. Jones RN, Bell JM, Sader HS et al. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagn Microbiol Infect Dis 2009; 63: 434-9.
49. Cirillo I, Vaccaro N, Evans R et al. Pharmacokinetics of doripenem in adults with cystic fibrosis. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, 2009. Abstract A1-017. American Society for Microbiology, Washington, DC, USA.
50. Shiba K, Nakashima M, Tanimura H et al. Pharmacokinetics and pharmacodynamics of S-4661, new parenteral carbapenem antibiotic. In: Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract F-217. American Society for Microbiology, Washington, DC, USA.
51. Cirillo I, Vaccaro N, Turner K et al. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009; 49: 798-806.
52. Zhanel GG, Ketter N, Rubinstein E et al. Overview of seizure-inducing potential of doripenem. Drug Saf 2009; 32: 709-16.
53. Zhanel GG, Lam A, Schweizer F et al. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9: 245-54.
54. Noel GJ, Strauss RS, Amsler K et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 37-44.
55. Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-55.
56. Nicholson SC, Strauss RA, Michiels B et al. Efficacy of ceftobiprole (BPR) compared to ceftriaxone (CTX) +/- linezolid (L) for the treatment of hospitalized community acquired pneumonia. In: Abstracts of the ATS International Conference, 2008, Toronto, Canada. Abstract C16.
57. European_Medicines_Agency. Refusal of the Marketing Authorisation for Zeftera (ceftobiprole). http://www.ema.europa.eu/pdfs/human/opinion/zeftera_qa_8378310.pdf (6 May 2010, date last accessed).
58. Health Canada. Health Canada Endorsed Important Information on Zeftera (Ceftobiprole) for Injection. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/zeftera_nth-aah-eng (6 May 2010, date last accessed).
59. Walkty A, Decorby M, Nichol K et al. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J Antimicrob Chemother 2008; 62: 206-8.
60. Wang H, Liu Y, Sun H et al. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China. Diagn Microbiol Infect Dis 2008; 62: 226-9.
61. Schirmer PL, Deresinski SC. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther 2009; 7: 777-91.
62. Banerjee R, Gretes M, Basuino L et al. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus (MRSA). Antimicrob Agents Chemother 2008; 52: 2089-96.
63. Bonfiglio G, Laksai Y, Franchino L et al. Mechanisms of β-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. J Antimicrob Chemother 1998; 42: 697-702.
64. Queenan A, Shang W, Crespo-Carbone S et al. Mechanisms of ceftobiprole and ceftazidime resistance development in Gram-negative clinical isolates from cSSSI subjects. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobials Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, 2008. Abstract CI-154. American Society for Microbiology, Washington, DC, USA.
65. Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against Gramnegative nonfermenters. Antimicrob Agents Chemother 2002; 46: 871-4.
66. Laohavaleeson S, Tessier PR, Nicolau DP, Pharamcodynamic comparison of ceftobiprole in pneumonia caused by phenotypically diverse Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2389-94.
67. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents 2009; 34: 15-20.
68. Page MG, Heim J. Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol 2009; 9: 558-65.
69. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
70. Page MGP, Desarbre E, Geier C et al. Activity of BAL30376 against Gram-negative bacteria. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract F1-312. American Society for Microbiology, Washington, DC, USA.
71. Falagas ME, Kastoris AC, Karageorgopoulos DE et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34:111-20.
72. Kent L, Bradley JM, France M et al. Temocillin in cystic fibrosis: a retrospective pilot study. J Cyst Fibros 2008; 7: 551-4.
73. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-43.
74. Keays T, Ferris W, Vandemheen KL et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009; 8: 122-7.
75. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366: 463-71.
76. Lodise TP, Patel N, Renaud-Mutart A et al. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis 2008; 61: 96-102.
77. Koga T, Masuda N, Kakuta M et al. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 2849-54.
78. Livermore DM, Mushtaq S, Ge Y et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009; 34: 402-6.
79. Zamorano L, Juan C, Fernandez-Olmos A et al. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aerugionsa isolates from chronically infected cystic fibrosis patients. Clin Microbiol Infect 2010; doi:10.1111/j.1469-0691.2009.03130.x.
80. Sham D, Pillar C, Brown N et al. Activity of ceftazidime/NXL104 and select comparators against geographically diverse clinical isolates of Pseudomonas aeruginosa.In:Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract E194. American Society for Microbiology, Washington, DC, USA.
81. Jones R, Armstrong ES, Aggen JB et al. Antimicrobial activity of ACHN-490, a neoglycoside, tested against a contemporary collection of clinical isolates including problematic antimicrobial-resistant phenotypes. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract E194. American Society for Microbiology, Washington, DC, USA.
82. Georgescu D, Martin D, Bratu S et al. Activity of ACHN-490, a novel neoglycoside antibiotic, against contemporary gram-negative clinical isolates from Brooklyn, NY hospitals. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract F1-842. American Society for Microbiology, Washington, DC, USA.
83. Cubist_Pharmaceuticals. In the Pipeline: Gram-negative CB-182, 804. http://www.cubist.com/products/cb-182_804.php (6 May 2010, date last accessed).
84. Petersen PJ, Jones CH, Venkatesan AM et al. Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem b-lactamase inhibitor BLI-489. Antimicrob Agents Chemother 2009; 53: 370-84.